Downregulation of RNA binding motif protein 17 expression inhibits proliferation of hypopharyngeal carcinoma FaDu cells

Han,Yuefeng; Zhang,Mingjie; Chen,Deshang; Li,Hui; Wang,Xiaomin; Ma,Shiyin

doi:10.3892/ol.2018.8012

Downregulation of RNA binding motif protein 17 expression inhibits proliferation of hypopharyngeal carcinoma FaDu cells

Authors:
- Yuefeng Han
- Mingjie Zhang
- Deshang Chen
- Hui Li
- Xiaomin Wang
- Shiyin Ma
View Affiliations

Affiliations: Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, P.R. China
Published online on: February 9, 2018 https://doi.org/10.3892/ol.2018.8012
Pages: 5680-5684
Copyright : © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RNA binding motif protein 17 (RBM17) is a protein-coding gene. The protein encoded by RBM17 is involved in the regulation of alternative splicing and is overexpressed in cancer. The present study aimed to determine the effect of RBM17-knockdown in hypopharyngeal carcinoma FaDu cells using the lentivirus‑mediated shRNA method. Cell proliferation was detected by an MTT assay. Flow cytometry analysis was used to determine cell cycle distribution and apoptosis. The results of the present study demonstrated that RBM17 expression was significantly decreased in FaDu cells infected with lentivirus‑shRNA. Knockdown of RBM17 expression by shRNA significantly reduced cell proliferation, augmented cell apoptosis and arrested cells at the G2/M phase in FaDu cells. The results of the present study indicate that RBM17 serves a notable role in cell proliferation, cell cycle progression and apoptosis of hypopharyngeal carcinoma cells.

View Figures

View References

1	Gooi Z, Fakhry C, Goldenberg D, Richmon J and Kiess AP; Education Committee of the American Head and Neck Society (AHNS), : AHNS Series: Do you know your guidelines? Principles of radiation therapy for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 38:987–992. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lewis CM, Hessel AC, Roberts DB, Guo YZ, Holsinger FC, Ginsberg LE, El-Naggar AK and Weber RS: Prereferral head and neck cancer treatment: Compliance with national comprehensive cancer network treatment guidelines. Arch Otolaryngol Head Neck Surg. 136:1205–1211. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hong YM, Gan WG and Xu ZH: Significance of the expression of integrin β1, VEGF and MVD in hypopharyngeal squamous cell carcinoma. Genet Mol Res. 13:6455–6465. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zvrko E, Mikic A and Vuckovic L: Clinicopathologic significance of CD105-assessed microvessel density in glottic laryngeal squamous cell carcinoma. Auris Nasus Larynx. 37:77–83. 2010. View Article : Google Scholar : PubMed/NCBI
5	Chien CY, Su CY, Hwang CF, Chuang HC, Hsiao YC, Wu SL and Huang CC: Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck. 28:441–446. 2006. View Article : Google Scholar : PubMed/NCBI
6	Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang X, Jin T, Cai XY, Liang Y, Hu WH and Kang T: Prognostic significance of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma. J Transl Med. 8:942010. View Article : Google Scholar : PubMed/NCBI
7	Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V and Shedd DP: Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 154:439–442. 1987. View Article : Google Scholar : PubMed/NCBI
8	Milisavljevic D, Stankovic M, Zivic M, Popovic M and Radovanović Z: Factors affecting results of treatment of Hypopharyngeal Carcinoma. Hippokratia. 13:154–160. 2009.PubMed/NCBI
9	Chu PY, Wang LW and Chang SY: Surgical treatment of squamous cell carcinoma of the hypopharynx: Analysis of treatment results, failure patterns, and prognostic factors. J Laryngol Otol. 118:443–449. 2004. View Article : Google Scholar : PubMed/NCBI
10	Chu PY and Chang SY: Reconstruction of the hypopharynx after surgical treatment of squamous cell carcinoma. J Chin Med Assoc. 72:351–355. 2009. View Article : Google Scholar : PubMed/NCBI
11	Black DL: Protein diversity from alternative splicing: A challenge for bioinformatics and post-genome biology. Cell. 103:367–370. 2000. View Article : Google Scholar : PubMed/NCBI
12	Zheng S: IRAS: High-throughput identification of novel alternative splicing regulators. Methods Enzymol. 572:269–289. 2016. View Article : Google Scholar : PubMed/NCBI
13	Hastings ML and Krainer AR: Functions of SR proteins in the U12-dependent AT-AC pre-mRNA splicing pathway. RNA. 7:471–482. 2001. View Article : Google Scholar : PubMed/NCBI
14	Manley JL and Tacke R: SR proteins and splicing control. Genes Dev. 10:1569–1579. 1996. View Article : Google Scholar : PubMed/NCBI
15	Mayeda A, Munroe SH, Cáceres JF and Krainer AR: Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 13:5483–5495. 1994.PubMed/NCBI
16	Neubauer G, King A, Rappsilber J, Calvio C, Watson M, Ajuh P, Sleeman J, Lamond A and Mann M: Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex. Nat Genet. 20:46–50. 1998. View Article : Google Scholar : PubMed/NCBI
17	Lallena MJ, Chalmers KJ, Llamazares S, Lamond AI and Valcárcel J: Splicing regulation at the second catalytic step by Sex-lethal involves 3′ splice site recognition by SPF45. Cell. 109:285–296. 2002. View Article : Google Scholar : PubMed/NCBI
18	Silverman EJ, Maeda A, Wei J, Smith P, Beggs JD and Lin RJ: Interaction between a G-patch protein and a spliceosomal DEXD/H-box ATPase that is critical for splicing. Mol Cell Biol. 24:10101–10110. 2004. View Article : Google Scholar : PubMed/NCBI
19	Svec M, Bauerová H, Pichová I, Konvalinka J and Strísovský K: Proteinases of betaretroviruses bind single-stranded nucleic acids through a novel interaction module, the G-patch. FEBS lett. 576:271–276. 2004. View Article : Google Scholar : PubMed/NCBI
20	Chaouki AS and Salz HK: Drosophila SPF45: A bifunctional protein with roles in both splicing and DNA repair. PLoS Genet. 2:e1782006. View Article : Google Scholar : PubMed/NCBI
21	Sampath J, Long PR, Shepard RL, Xia X, Devanarayan V, Sandusky GE, Perry WL III, Dantzig AH, Williamson M, Rolfe M and Moore RE: Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol. 163:1781–1790. 2003. View Article : Google Scholar : PubMed/NCBI
22	Sakoda T, Kasahara N, Hamamori Y and Kedes L: A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol. 31:2037–2047. 1999. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Perry WL III, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW, Jin S, Lesoon A, O'Brien KA, Peek VL, et al: Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed-a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 65:6593–6600. 2005. View Article : Google Scholar : PubMed/NCBI
25	Al-Ayoubi AM, Zheng H, Liu Y, Bai T and Eblen ST: Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Mol Cell Biol. 32:2880–2893. 2012. View Article : Google Scholar : PubMed/NCBI
26	Liu Y, Conaway L, Rutherford Bethard J, Al-Ayoubi AM, Thompson Bradley A, Zheng H, Weed SA and Eblen ST: Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res. 41:4949–4962. 2013. View Article : Google Scholar : PubMed/NCBI
27	Kuntz K and O'Connell MJ: The G(2) DNA damage checkpoint: Could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther. 8:1433–1439. 2009. View Article : Google Scholar : PubMed/NCBI
28	Bucher N and Britten CD: G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 98:523–528. 2008. View Article : Google Scholar : PubMed/NCBI